GSK ready to market Amgen's new bone drug

Fresh off European approval of Amgen's (NASDAQ: AMGN) much-anticipated bone drug Prolia (denosumab), GlaxoSmithKline (NYSE: GSK) will be gearing up to collaborate with the biotech on commercializing the potential blockbuster drug in Europe. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.